Adenosine Acts Through A2AR to Alleviate the Inflammatory Response Caused by Activation of Perivascular-Resident

Wenya Fan1, Jiale Lv1, Lingling Neng1

  • 1Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China.

Abstract

Insights

Adenosine, acting through the A2A receptor (A2AR), reduces inflammation in inner ear cells. This finding suggests A2AR as a potential target for treating hearing impairments caused by blood labyrinth barrier disruption.

Area of Science:

  • Inner ear biology
  • Neuroimmunology
  • Otopathology

Background:

  • Disruption of the blood labyrinth barrier (BLB) is a key factor in hearing loss.
  • Perivascular-resident macrophage-like melanocytes (PVM/Ms) are crucial for BLB integrity.
  • PVM/Ms activation decreases pigment epithelium-derived factor (PEDF), leading to BLB breakdown.

Purpose of the Study:

  • Investigate the role of the adenosine A2A receptor (A2AR) pathway in lipopolysaccharide (LPS)-induced inflammation in PVM/Ms.
  • Elucidate the mechanisms underlying A2AR's effect on PVM/Ms and BLB integrity.

Main Methods:

  • Evaluated adenosine and A2AR effects on LPS-induced PVM/Ms.
  • Quantified inflammatory markers (TNF-α, IL-6, TIMP-1, MMP-9) and PEDF using qRT-PCR, ELISA, and Western blot.
  • Assessed BLB permeability in an EC-PVM/M co-culture model.

Main Results:

  • Adenosine treatment abrogated LPS-induced changes in inflammatory factors and MMP-9.
  • Adenosine reduced reactive oxygen species (ROS) and PVM/Ms activation.
  • The p38 MAPK pathway was implicated in adenosine's regulatory effects.

Conclusions:

  • Adenosine, via A2AR, attenuates PVM/Ms inflammatory activation and enhances endothelial barrier integrity.
  • Adenosine and A2AR represent potential therapeutic targets for hearing impairments.

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.4K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.6K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
4.6K